AssetMark Inc
XENE icon

AssetMark Inc’s Xenon Pharmaceuticals XENE Stock Holding History

AssetMark Inc’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.17M Sell
19,334
-938
-5% -$52.1K ﹤0.01% 1063
2026
Q1 		$1.18M Sell
20,272
-997
-5% -$45.9K ﹤0.01% 1012
2025
Q4 		$953K Sell
21,269
-1,297
-6% -$54.5K ﹤0.01% 1025
2025
Q3 		$906K Buy
22,566
+1,316
+6% +$46.4K ﹤0.01% 992
2025
Q2 		$665K Buy
21,250
+1,316
+7% +$42.9K ﹤0.01% 998
2025
Q1 		$669K Sell
19,934
-1,651
-8% -$62.7K ﹤0.01% 930
2024
Q4 		$846K Buy
21,585
+1,915
+10% +$79.2K ﹤0.01% 877
2024
Q3 		$774K Buy
19,670
+1,435
+8% +$57.9K ﹤0.01% 828
2024
Q2 		$711K Buy
18,235
+5,050
+38% +$202K ﹤0.01% 824
2024
Q1 		$568K Buy
13,185
+3,247
+33% +$149K ﹤0.01% 812
2023
Q4 		$458K Buy
9,938
+2,835
+40% +$100K ﹤0.01% 802
2023
Q3 		$243K Buy
7,103
+1,258
+22% +$47.1K ﹤0.01% 845
2023
Q2 		$225K Buy
+5,845
New +$232K ﹤0.01% 827

Other funds holding XENE

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return

AssetMark Inc's XENE Position: Q2 2026 in Review

AssetMark Inc reduced its Xenon Pharmaceuticals (XENE) stake by 4.6% in Q2 2026, selling an estimated $52.1K and leaving 19,334 shares worth $1.17M. The position accounts for ﹤0.01% of the portfolio, ranked #1063.

AssetMark Inc first reported a position in XENE in Q2 2023 and has held it in 13 quarters since. The position peaked at $1.18M in Q1 2026. 52 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • AssetMark Inc held 19,334 shares of Xenon Pharmaceuticals worth $1.17M as of Q2 2026.
  • AssetMark Inc sold 938 Xenon Pharmaceuticals shares in Q2 2026, an estimated $52.1K.
  • Xenon Pharmaceuticals made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #1063 holding.
  • AssetMark Inc first reported a position in Xenon Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • AssetMark Inc's Xenon Pharmaceuticals position peaked at $1.18M in Q1 2026.
  • 52 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.